Identification of novel prognostic markers for Chronic Lymphocytic Leukemia (CLL).
Cull G, Downs AM, Davies J

Well characterised prognostic markers for chronic lymphocytic leukemia (CLL) measured using established methods including flow cytometry and fluorescence in situ hybridisation (FISH) will be compared with potential novel prognostic markers identified by newly developed DNA microarray technology.

Cytokine profiles and microarray gene expression in juvenile idiopathic arthritis.
Downs AM, Murray K

A study of plasma and synovial fluid cytokine levels and cytokine gene expression in children with juvenile idiopathic arthritis of varying degrees of severity.

Characterisation of an osteoclast cell model by microarray.
Downs AM, Xu J

Microarray analysis of gene expression changes during differentiation of the RAW mouse monocytic cell line to osteoclast-like cells, which are used in in vitro studies of bone metabolism.

Microarray analysis of chromosome 13q deletion in multiple myeloma.
O'Reilly J, Downs AM, Strurm MJ, Erber WN, Herrmann RP

A comparison of gene expression patterns in malignant plasma cells from multiple myeloma patients with and without the chromosome 13q deletion which is defined as a marker of poor prognosis in this patient cohort.

Microarray analysis of lymphoma subtypes.
Spagnolo DV, Downs AM

Microarray analysis of lymphoma tissues will identify differences in gene expression between lymphoma subtypes with possible relevance to disease progression.

DNA microarrays for the detection and characterisation of influenza.
Smith D, Broom A, Hampson A, Barr I, Downs AM

A novel microarray method will be developed for rapid subtyping of influenza strains.

Effect of aprotinin and factor V Leiden on haemostasis in cardiac surgical patients.
Linden MD , Schneider M, Baker S, Erber WN

Uses in vitro and in vivo studies and a novel ex vivo model of cardiopulmonary bypass to evaluate the effect of the pharmacological blood conservation agent, aprotinin, and the genetic risk factor for thrombosis, factor V Leiden, on haemostatic risk for coronary graft occlusion in cardiac surgical patients.

Effect of heparin bonded circuits on haemostasis.
Linden MD , Schneider M, Baker S, Erber WN

This study uses a novel ex vivo model to evaluate the effect of heparin bonded cardiopulmonary bypass circuits and a reduced systemic dose of heparin on peri-operative coagulation and platelet activation.

Antithrombin and heparin resistance.
Linden MD , Schneider M, Baker S, Erber WN

This study investigates acquired antithrombin deficiency as the mechanism of heparin resistance during cardiopulmonary bypass in patients who receive pre-operative intravenous heparin therapy for unstable angina.

Antithrombin and acute normovolaemic haemodilution.
Linden MD, Gibbs NM, Bremmer M, Schneider M, Weightman W, Erber WN

This study evaluates the effect of acute normovolaemic haemodilution and cardiopulmonary bypass on intra-operative antithrombin concentrations.

Coagulation testing in the presence of high dose heparin.
Linden MD , Michalopoulos N, Erber WN

This study evaluates use of the ion exchange resin tri-ethylaminoethyl cellulose (TEAEC) for the removal of high dose heparin from a clinical blood sample and the effect of TEAEC on coagulation parameters.

Mechanisms of post-operative haemorrhage in cardiac surgical patients.
Linden MD , Schneider M, Gibbs NM , Erber WN

This study investigates whether residual heparin, heparin rebound, or excess protamine sulphate contribute to post-operative bleeding in cardiac surgical patients.